Overview

Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in an onchocerciasis endemic area.
Phase:
Phase 3
Details
Lead Sponsor:
Medicines Development for Global Health
Treatments:
Ivermectin
Milbemycin
Moxidectin